Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI evaluation states both warning elements are supported by the provided CAPLYTA prescribing information, matching the label content in Sections 5.1/8.5 (increased mortality in elderly dementia-related psychosis) and 5.2/8.4 (suicidal thoughts/behaviors).
Category Scores
Accurate Statements
Increased mortality in elderly dementia-related psychosis: The label states elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death, and CAPLYTA is not approved for dementia-related psychosis.
Supported by Label 5.1 (increased risk of death; CAPLYTA not approved for dementia-related psychosis) and reiterated in 8.5.
Suicidal thoughts and behaviors: The label describes increased incidence of suicidal thoughts and behaviors in antidepressant-treated pediatric and young adult patients and provides monitoring/management recommendations.
Supported by Label 5.2 (suicidal thoughts/behaviors; monitoring and management language) and referenced in 8.4.
Overall conclusion: Both warning elements align with FDA-approved labeling sections cited.
Consistent with the provided label excerpts for both warnings.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The AI response only asserts label-support status for the specified warnings and does not provide dosing, administration, or other clinical directives beyond what the label excerpts support.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor formatting/duplication in the provided AI text does not affect the substantive label-evidence claims.
Suggested Improvement
Present a single consolidated evaluation structure to avoid redundancy, while retaining the same label-supported conclusions.